
Italian neuroscience company Newron Pharmaceuticals (SIX: NWRN; XETRA: NP5) has set out the US Food and Drug Administration's (FDA) reasons for the clinical hold at US sites in its Phase III ENIGMA-TRS 2 trial of evenamide in treatment-resistant schizophrenia (TRS), and said it is preparing a response.
According to Newron, the FDA's written communication cites the known risk that some sodium channel blockers can trigger arrhythmias, which in turn can lead to serious cardiovascular events or seizures.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze